


-93-

## CLAIMS

What is claimed is:




1. A compound of the Formula I



I

5

wherein



each R' is independently hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

10

R<sup>1</sup> and R<sup>2</sup> are independently hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl,

-OH, -(CH<sub>2</sub>)<sub>n</sub> aryl,

-(CH<sub>2</sub>)<sub>n</sub>-substituted aryl,

-(CH<sub>2</sub>)<sub>n</sub>-O-aryl,

-(CH<sub>2</sub>)<sub>n</sub>-O-substituted aryl,

15

-(CH<sub>2</sub>)<sub>n</sub>-S-aryl,

-(CH<sub>2</sub>)<sub>n</sub>-S-substituted aryl,

-(CH<sub>2</sub>)<sub>n</sub>-S-heteroaryl,

-94-

-(CH<sub>2</sub>)<sub>n</sub>-S-substituted heteroaryl,

-(CH<sub>2</sub>)<sub>n</sub>-NR'-aryl,

-(CH<sub>2</sub>)<sub>n</sub>-NR'-substituted aryl,

-(CH<sub>2</sub>)<sub>n</sub>-NR'-heteroaryl,

5       -(CH<sub>2</sub>)<sub>n</sub>-NR'-substituted heteroaryl,

-(CH<sub>2</sub>)<sub>n</sub>-heteroaryl, or





-(CH<sub>2</sub>)<sub>n</sub>-substituted heteroaryl;

each n is independently 0 to 6;





R<sup>3</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

10       R<sup>4</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl or hydrogen; and

X is hydrogen,



-95-


 $-(\text{CH}_2)_n-\text{S}-(\text{CH}_2)_n-\text{aryl},$ 
 $-(\text{CH}_2)_n-\text{S}-(\text{CH}_2)_n-\text{substituted aryl},$ 


and the pharmaceutically acceptable salts thereof.

2. A compound in accordance with Claim 1 wherein R' is hydrogen or methyl.

10 3. A compound in accordance with Claim 1 wherein each R' is hydrogen.

4. A compound in accordance with Claim 1 wherein R<sup>3</sup> is hydrogen, and R<sup>4</sup> is methyl, ethyl, or isopropyl.

-96-

5. A compound in accordance with Claim 1 wherein

$R^1$  is hydrogen or methyl; and

$R^2$  is  $-(CH_2)_n$ -phenyl,

hydrogen,

$-(CH_2)_n$ -O-phenyl,


-OH,

$-(CH_2)_n$ -benzimidazolyl,


$-(CH_2)_n$ -indolyl, or

$-(CH_2)_n$ -phenol.



6. A compound in accordance with Claim 1 wherein






7. A compound in accordance with Claim 1 wherein




X is hydrogen,



-97-




, or




5

8. A compound of the Formula I:





I

wherein



-98-



each R' is independently hydrogen or methyl;


each n is independently 1, 2 to 3;

5 R<sup>1</sup> and R<sup>2</sup> are independently hydrogen,





-(CH<sub>2</sub>)<sub>n</sub>-phenyl,

-(CH<sub>2</sub>)<sub>n</sub>-O-phenyl,





-OH,








10



-99-



5



10


$\text{R}^a$ ,  $\text{R}^b$ , and  $\text{R}^c$  are independently halogen,  $-\text{OC}_1-\text{C}_6$  alkyl or hydrogen;

$\text{R}^3$  is hydrogen;





$\text{R}^4$  is methyl, ethyl, or isopropyl; and

$\text{X}$  is hydrogen,


-100-



5



10



and the pharmaceutically acceptable salts thereof.

9. A compound in accordance with Claim 1 wherein  $\text{R}^1$  is hydrogen and



-101-

$R^2$  is  $-(CH_2)_n$ -indolyl,  
 $-(CH_2)_n$ -NH-phenyl,  
 $-(CH_2)_n$ -O-phenyl,  
 $-(CH_2)_n$ -substituted indolyl,  
5  $-(CH_2)_n$ -tetrazolyl,  
 $-(CH_2)_n$ -phenyl,  
 $-(CH_2)_n$ -substituted phenyl,  
 $-(CH_2)_n$ -substituted benzimidazolyl,  
 $-(CH_2)_n$ -benztriazolyl,  
10  $-(CH_2)_n$ -indazolyl,  
 $-(CH_2)_n$ -benzimidazolyl,  
 $-(CH_2)_n$ -pyridyl,  
 $-(CH_2)_n$ -naphthyl, or  
 $-(CH_2)_n$ -quinolinyl.

15 10. The compound:

3-(2-Methyl-3-phenethylcarbamoyl-propionylamino)-4-oxo-5-(2-phenyl-ethanesulfonylamino)-pentanoic acid;

3-(2-Carbamoylmethyl-3-methyl-butyrylamino)-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid;

20 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-[3-methyl-2-(phenethylcarbamoyl-methyl)-butyrylamino]-4-oxo-pentanoic acid;

3-(2-Carbamoylmethyl-3-methyl-butyrylamino)-4-oxo-5-(2-phenyl-ethanesulfonyl-amino)-pentanoic acid;

25 3-[3-Methyl-2-(phenethylcarbamoyl-methyl)-butyrylamino]-4-oxo-5-(2-phenyl-ethanesulfonylamino)-pentanoic acid;

5-(7,7-Dimethyl-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-[3-methyl-2-(phenethylcarbamoyl-methyl)-butyrylamino]-4-oxo-pentanoic acid;

-102-

(S,S)-3-{3-Methyl-2-[(3-phenyl-propylcarbamoyl)-methyl]-butyrylamino}-4-oxo-butyric acid;

3-{3-Methyl-2-[(3-phenoxy-ethylcarbamoyl)-methyl]-butyrylamino}-4-oxo-butyric acid;

5 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-{3-methyl-2-[(2-phenoxy-ethylcarbamoyl)-methyl]-butyrylamino}-4-oxo-pentanoic acid;

3-[3-Methyl-2-(phenethylcarbamoyl-methyl)-butyrylamino]-4-oxo-5-(3-phenyl-propylsulfanyl)-pentanoic acid;

10 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-{3-methyl-2-[(methyl-phenethyl-carbamoyl)-methyl]-butyrylamino}-4-oxopentanoic acid;

5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-{3-methyl-2-[(3-phenyl-propylcarbamoyl)-methyl]-butyrylamino}-4-oxo-pentanoic acid;

15 3-{3-Methyl-2-[(3-phenyl-propylcarbamoyl)-methyl]-butyrylamino}-4-oxo-5-(2-oxo-2H-chromen-6-yloxy)-pentanoic acid;

5-[3-(1H-Imidazol-2-yl)-naphthalen-2-yloxy]-3-{3-methyl-2-[(3-phenyl-propylcarbamoyl)-methyl]-butyrylamino}-4-oxo-pentanoic acid;

20 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-(2-hydroxycarbamoylmethyl-3-methyl-butylamino)-4-oxo-pentanoic acid;

5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-(2-{[2-(1H-indol-3-yl)-ethylcarbamoyl]-methyl}-3-methyl-butylamino)-4-oxo-pentanoic acid; or

25 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-{3-methyl-2-[[3-(4-hydroxyphenyl)-propylcarbamoyl]-methyl]-butyrylamino}-4-oxo-pentanoic acid.

11. The compound:

30 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-(2-{[2-(1H-indol-3-yl)-ethylcarbamoyl]-methyl}-3-methyl-butyl amino)-4-oxo-pentanoic acid;

-103-

5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-(2-{[2-(1H-indol-3-yl)-ethylcarbamoyl]-methyl}-3-methyl-butyrylamino)-4-oxo-pentanoic acid;

5 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-(3-methyl-2-{[2-(1-methyl-1H-indol-3-yl)-ethylcarbamoyl]-methyl}-butyrylamino)-4-oxo-pentanoic acid;

10 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-(3-methyl-2-{[2-(7-methyl-1H-indol-3-yl)-ethylcarbamoyl]-methyl}-butyrylamino)-4-oxo-pentanoic acid;

10 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-(2-{[2-(6-fluoro-1H-indol-3-yl)-ethylcarbamoyl]-methyl}-3-methyl-butyrylamino)-4-oxo-pentanoic acid;

15 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-[3-methyl-2-({methyl-[2-(1-methyl-1H-indol-3-yl)-ethyl]-carbamoyl}-methyl)-butyrylamino]-4-oxo-pentanoic acid;

3-{2-[(2-Benzoimidazol-1-yl-ethylcarbamoyl)-methyl]-3-methyl-butyrylamino}-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid;

20 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-(3-methyl-2-{[2-(1H-tetrazol-5-yl)-ethylcarbamoyl]-methyl}-butyrylamino)-4-oxo-pentanoic acid;

5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-3-{2-[(3-phenyl-propylcarbamoyl)-methyl]-butyrylamino}-pentanoic acid;

25 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-(2-{[2-(1-methyl-1H-indol-3-yl)-ethylcarbamoyl]-methyl}-butyrylamino)-4-oxo-pentanoic acid;

3-(3-Methyl-2-{[2-(1-methyl-1H-indol-3-yl)-ethylcarbamoyl]-methyl}-butyrylamino)-4-oxo-butyric acid;

30 3-[3-Methyl-2-({methyl-[2-(1-methyl-1H-indol-3-yl)-ethyl]-carbamoyl}-methyl)-butyrylamino]-4-oxo-butyric acid;

3-{2-[(2-Benzoimidazol-1-yl-ethylcarbamoyl)-methyl]-3-methyl-butyrylamino}-4-oxo-butyric acid;

5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-(2-{[3-(4-hydroxy-phenyl)-propylcarbamoyl]-methyl}-3-methyl-butyrylamino)-4-oxo-pentanoic acid;

5 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-{3-methyl-2-[(2-pyridin-4-yl-ethylcarbamoyl)-methyl]-butyrylamino}-4-oxo-pentanoic acid;

5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-{3-methyl-2-[(2-naphthalen-2-yl-ethylcarbamoyl)-methyl]-butyrylamino}-4-oxo-pentanoic acid;

10 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-{3-methyl-2-[(3-pyridin-4-yl-propylcarbamoyl)-methyl]-butyrylamino}-4-oxo-pentanoic acid;

5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-{3-methyl-2-[(3-quinolin-2-yl-propylcarbamoyl)-methyl]-butyrylamino}-4-oxo-pentanoic acid;

15 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-{3-methyl-2-[(3-naphthalen-2-yl-propylcarbamoyl)-methyl]-butyrylamino}-4-oxo-pentanoic acid; or

20 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-{3-methyl-2-[(3-pyridin-3-yl-propylcarbamoyl)-methyl]-butyrylamino}-4-oxo-pentanoic acid.

12. The compound:

25 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-{3-methyl-2-[(2-naphthalen-2-yl-ethylcarbamoyl)-methyl]-butyrylamino}-4-oxo-pentanoic acid;

5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-(3-methyl-2-{[2-(7-methyl-1H-indol-3-yl)-ethylcarbamoyl]-methyl}-butyrylamino)-4-oxo-pentanoic acid;

30 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-(2-{[2-(6-fluoro-1H-indol-3-yl)-ethylcarbamoyl]-methyl}-3-methyl-butyrylamino)-4-oxo-pentanoic acid;

-105-

3-[3-Methyl-2-({methyl-[2-(1-methyl-1H-indol-3-yl)-ethyl]-  
carbamoyl}-methyl)-butyrylamino]-4-oxo-butyric acid;

3-(3-Methyl-2-{{methyl-(2-phenoxy-ethyl)-carbamoyl}-methyl}-  
butyrylamino)-4-oxo-butyric acid;

5 3-(2-{{2-(5,6-Dimethyl-benzoimidazol-1-yl)-ethylcarbamoyl]-  
methyl}-3-methyl-butyrylamino)-4-oxo-butyric acid, trifluoroacetate salt;

5-(7,7-Dimethyl-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-  
3-{3-methyl-2-[(3-phenyl-propylcarbamoyl)-methyl]-butyrylamino}-  
4-oxo-pentanoic acid;

10 5-(7,7-Dimethyl-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-  
3-(2-{{2-(1H-indol-3-yl)-ethylcarbamoyl]-methyl}-3-methyl-  
butyrylamino)-4-oxo-pentanoic acid;

5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-  
ylmethanesulfonylamino)-3-{3-methyl-2-[(3-pyridin-4-yl-  
propylcarbamoyl)-methyl]-butyrylamino}-4-oxo-pentanoic acid;

15 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-  
ylmethanesulfonylamino)-3-{3-methyl-2-[(3-quinolin-2-yl-  
propylcarbamoyl)-methyl]-butyrylamino}-4-oxo-pentanoic acid;

5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-  
ylmethanesulfonylamino)-3-{3-methyl-2-[(3-naphthalen-1-yl-  
propylcarbamoyl)-methyl]-butyrylamino}-4-oxo-pentanoic acid;

20 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-  
ylmethanesulfonylamino)-3-{3-methyl-2-[(3-pyridin-3-yl-  
propylcarbamoyl)-methyl]-butyrylamino}-4-oxo-pentanoic acid; or

25 3-{2-[(2-Benzoimidazol-1-yl-ethylcarbamoyl)-methyl]-3-methyl-  
butyrylamino}-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-  
ylmethanesulfonylamino)-4-oxo-pentanoic acid.

13. The compound:

30 5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-  
ylmethanesulfonylamino)-3-(3-methyl-2-{{2-(1-methyl-1H-indol-3-yl)-  
ethylcarbamoyl]-methyl}-butyrylamino)-4-oxo-pentanoic acid;

-106-

5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-{3-methyl-2-[(2-pyridin-4-ylethylcarbamoyl)-methyl]-butyrylamino}-4-oxo-pentanoic acid;

5 3-(2-{[2-(5-Acetyl-1H-indol-3-yl)-ethylcarbamoyl]-methyl}-3-methyl-butylamino)-5-(7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-4-oxo-pentanoic acid;

5-(7,7-Dimethyl-2-oxo-bicyclo[2.2.1]hept-1-ylmethanesulfonylamino)-3-(3-methyl-2-{[2-(1H-tetrazol-5-yl)-ethylcarbamoyl]-methyl}-butyrylamino)-4-oxo-pentanoic acid;

10 N<sup>4</sup>-(2-Benzimidazol-1-yl-ethyl)-N<sup>1</sup>-(2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-2-isopropyl-succinamide;

N<sup>1</sup>-(2-Ethoxy-5-oxo-tetrahydro-furan-3-yl)-N<sup>4</sup>-[2-(1H-indol-3-yl)-ethyl]-2-isopropyl-succinamide;

15 N<sup>1</sup>-(2-Ethoxy-5-oxo-tetrahydro-furan-3-yl)-2-isopropyl-N<sup>4</sup>-[2-(1-methyl-1H-indol-3-yl)-ethyl]-succinamide;

N<sup>4</sup>-[2-(5,6-Dichloro-benzimidazol-1-yl)-ethyl]-N<sup>1</sup>-(2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-2-isopropyl-succinamide;

N<sup>1</sup>-(2-Ethoxy-5-oxo-tetrahydro-furan-3-yl)-2-isopropyl-N<sup>4</sup>-(2-phenoxy-ethyl)-succinamide; or

20 N<sup>1</sup>-(2-Ethoxy-5-oxo-tetrahydro-furan-3-yl)-2-isopropyl-N<sup>4</sup>-[2-(6-methoxy-1H-indol-3-yl)-ethyl]-succinamide.

14. The compound:

N<sup>4</sup>-(2-Benzotriazol-1-yl-ethyl)-N<sup>1</sup>-(2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-2-isopropyl-succinamide;

25 N<sup>1</sup>-(2-Ethoxy-5-oxo-tetrahydro-furan-3-yl)-N<sup>4</sup>-(2-indazol-1-yl-ethyl)-2-isopropyl-succinamide;

N<sup>1</sup>-(2-Ethoxy-5-oxo-tetrahydro-furan-3-yl)-2-isopropyl-N<sup>4</sup>-(2-phenylamino-ethyl)-succinamide;

30 N<sup>1</sup>-(2-Ethoxy-5-oxo-tetrahydro-furan-3-yl)-N<sup>4</sup>-[2-(6-fluoro-1H-indol-3-yl)-ethyl]-2-isopropyl-succinamide;

$N^1$ -(2-Ethoxy-5-oxo-tetrahydro-furan-3-yl)- $N^4$ -[2-(7-methyl-1H-indol-3-yl)-ethyl]-2-isopropyl-succinamide;

$N^1$ -(2-ethoxy-5-oxotetrahydro-furan-3-yl)-2-isopropyl- $N^4$ -[2-(2-methyl-benzoimidazol-1-yl)-ethyl]-succinamide;

5  $N^1$ -(2-Ethoxy-5-oxo-tetrahydro-furan-3-yl)-2-isopropyl- $N^4$ -[3-(3,4,5-trimethoxy-phenyl)-propyl]-succinamide;

$N^1$ -(2-Ethoxy-5-oxo-tetrahydro-furan-3-yl)-2-isopropyl- $N^4$ -[2-(phenyl)-ethyl]-succinamide;

10  $N^1$ -(2-Ethoxy-5-oxo-tetrahydro-furan-3-yl)-2-isopropyl- $N^4$ -[4-(phenyl)-butyl]-succinamide; or

$N^1$ -(2-Ethoxy-5-oxo-tetrahydro-furan-3-yl)- $N^4$ -(2-indol-1-yl-ethyl)-2-isopropyl-succinamide.

15. The compound:

15  $N^1$ -(2-Ethoxy-5-oxo-tetrahydro-furan-3-yl)-2-isopropyl- $N^4$ -[4-(phenyl)-propyl]-succinamide;

$N^1$ -(2-Ethoxy-5-oxo-tetrahydro-furan-3-yl)- $N^4$ -[2-(5-fluoro-1H-indol-3-yl)-ethyl]-2-isopropyl-succinamide;

3-{2-[(2-Benzoimidazol-1-yl-ethyl)carbamoyl]-methyl}-3-methyl-butrylamino}-4-oxo-butyric acid;

20 3-(3-Methyl-2-[[2-(1-methyl-1H-indol-3-yl)-ethyl)carbamoyl]-methyl]-butrylamino)-4-oxo-butyric acid;

3-(2-[[2-(5-Fluoro-1-methyl-1H-indol-3-yl)-ethyl)carbamoyl]-methyl]-3-methyl-butrylamino)-4-oxo-butyric acid;

25 3-(2-[[2-(5,6-Dichloro-benzoimidazol-1-yl)-ethyl)carbamoyl]-methyl]-3-methyl-butrylamino)-4-oxo-butyric acid;

3-(2-[[2-(2-Benzoimidazol-1-yl-ethyl)-methyl-carbamoyl]-methyl]-3-methyl-butrylamino)-4-oxo-butyric acid;

3-{2-[(2-Benzotriazol-1-yl-ethyl)carbamoyl]-methyl}-3-methyl-butrylamino}-4-oxo-butyric acid;

30 3-{2-[(2-Indazol-1-yl-ethyl)carbamoyl]-methyl}-3-methyl-butrylamino}-4-oxo-butyric acid;

-108-

- 3-[2-([2-(5,6-Dimethyl-benzoimidazol-1-yl)-ethyl]-methylcarbamoyl)-methyl)-3-methyl-butyrylamino]4-oxo-butyric acid;  
3-[2-([2-(2-Methyl-benzoimidazol-1-yl)-ethyl]-methylcarbamoyl)-methyl)-3-methyl-butyrylamino]4-oxo-butyric acid;  
5 3-(3-methyl-2-{[3-(3,4,5-trimethoxy-pheny)-propylcarbamoyl]-methyl}-butyrylamino)-4-oxo-butyric acid;  
3-{3-Methyl-2-[(2-phenoxy-ethylcarbamoyl)-methyl]-butyrylamino}-4-oxo-butyric acid ethyl ester;  
3-Cyano-3-{3-methyl-2-[(2-phenoxy-ethylcarbamoyl)-methyl]-butyrylamino}-propionic acid ethyl ester; or  
10 3-Cyano-3-{3-methyl-2-[(2-phenoxy-ethylcarbamoyl)-methyl]-butyrylamino}-propionic acid.
16. A pharmaceutical composition that comprises a compound of Claim 1.
17. A pharmaceutical composition that comprises a compound of Claim 8.
- 15 18. A method of treating or preventing stroke, the method comprising administration to a patient having, having had, or at risk of having a stroke a therapeutically effective amount of a compound of Claim 1.
19. A method of treating or preventing stroke, the method comprising administration to a patient having, having had, or at risk of having a stroke  
20 a therapeutically effective amount of a compound of Claim 8.
20. A method of treating inflammatory diseases, the method comprising administering to a patient having an inflammatory disease a therapeutically effective amount of a compound of Claim 1.
- 25 21. A method of treating inflammatory diseases, the method comprising administering to a patient having an inflammatory disease a therapeutically effective amount of a compound of Claim 8.



-109-

22. The method of Claim 20 wherein the inflammatory disease is rheumatoid arthritis or inflammatory bowel disease.
23. The method of Claim 21 wherein the inflammatory disease is rheumatoid arthritis or inflammatory bowel disease.
- 5 24. A method of treating septic shock, the method comprising administering to a patient having septic shock a therapeutically effective amount of a compound of Claim 1.
- 10 25. A method of treating septic shock, the method comprising administering to a patient having septic shock a therapeutically effective amount of a compound of Claim 8.
26. A method of treating reperfusion injury, the method comprising administering to a patient having reperfusion injury a therapeutically effective amount of a compound of Claim 1.
- 15 27. A method of treating reperfusion injury, the method comprising administering to a patient having reperfusion injury a therapeutically effective amount of a compound of Claim 8.
28. A method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Claim 1.
- 20 29. A method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Claim 8.
- 25 30. A method of treating shigellosis, the method comprising administering to a patient having shigellosis a therapeutically effective amount of a compound of Claim 1.

-110-

31. A method of treating shigellosis, the method comprising administering to a patient having shigellosis a therapeutically effective amount of a compound of Claim 8.
- 5 32. A method of treating multiple sclerosis, the method comprising administering to a patient having multiple sclerosis a therapeutically effective amount of a compound of Claim 1.
33. A method of treating multiple sclerosis, the method comprising administering to a patient having multiple sclerosis a therapeutically effective amount of a compound of Claim 8.
- 10 34. A method of inhibiting interleukin-1 $\beta$  converting enzyme, the method comprising administering to a patient in need of interleukin-1 $\beta$  converting enzyme inhibition a therapeutically effective amount of a compound of Claim 1.
- 15 35. A method of inhibiting interleukin-1 $\beta$  converting enzyme, the method comprising administering to a patient in need of interleukin-1 $\beta$  converting enzyme inhibition a therapeutically effective amount of a compound of Claim 8.